Diffuse cutaneous systemic sclerosis

Diffuse cutaneous systemic sclerosis (dcSSc) is a severe subtype of systemic sclerosis (scleroderma) characterized by widespread skin thickening that extends proximal to the elbows and knees and may involve the trunk. It is a chronic autoimmune connective tissue disorder in which excessive collagen deposition leads to fibrosis of the skin and internal organs. The disease results from a combination of vascular damage, immune system activation, and progressive fibrosis. Diffuse cutaneous systemic sclerosis is distinguished from the limited cutaneous form by its more rapid onset, more extensive skin involvement, and higher risk of serious internal organ complications. The disease affects multiple body systems. Skin fibrosis can cause significant tightening and contractures of the fingers, hands, and limbs. Raynaud's phenomenon (episodic color changes in the fingers and toes triggered by cold or stress) is nearly universal and often one of the earliest symptoms. Internal organ involvement is a hallmark of dcSSc and may include interstitial lung disease (pulmonary fibrosis), pulmonary arterial hypertension, renal crisis (a potentially life-threatening complication involving sudden severe hypertension and kidney failure), gastrointestinal dysmotility (difficulty swallowing, acid reflux, bloating, and malabsorption), and cardiac fibrosis leading to arrhythmias or heart failure. Anti-topoisomerase I (anti-Scl-70) antibodies and anti-RNA polymerase III antibodies are commonly associated with this subtype. There is currently no cure for diffuse cutaneous systemic sclerosis, but treatment focuses on managing symptoms and slowing disease progression. Immunosuppressive therapies such as mycophenolate mofetil, methotrexate, and cyclophosphamide are used to address skin and lung fibrosis. ACE inhibitors have dramatically improved outcomes in scleroderma renal crisis. Autologous hematopoietic stem cell transplantation (AHSCT) has shown benefit in selected patients with severe, progressive disease. Nintedanib and tocilizumab have been approved or studied for scleroderma-associated interstitial lung disease. Multidisciplinary care involving rheumatology, pulmonology, cardiology, gastroenterology, and nephrology is essential for optimal management.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Diffuse cutaneous systemic sclerosis